112
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

DEVELOPMENT OF LLE AND SPE PROCEDURES AND ITS APPLICATIONS FOR DETERMINATION OF OLMESARTAN IN HUMAN PLASMA USING RP-HPLC AND HPTLC

, , , &
Pages 423-430 | Published online: 08 Feb 2010
 

Abstract

Two novel simple and rapid liquid–liquid and solid phase extraction methods have been developed for determination of olmesartan in human plasma using zidovudine as an internal standard. Liquid–liquid extraction from spiked human plasma samples was done using Dichloromethane: acetic acid (5.5: 0.5, v/v) solvent, while solid phase extraction was carried out on a DSC MCAX cartridge. For HPLC, the mobile phase consisted of water acetic acid pH 4.5 and methanol (25:75) at a flow rate of 0.5 mL · min−1 in isocratic mode. The calibration curve was plotted with a concentration range 10 μgmL−1 to 60 μgmL−1. Recovery studies were carried out by LLE and SPE procedures with average recoveries 69.27% and 72.87%, respectively. For HPTLC the developing phase consisting of ethyl acetate methanol and acetic acid (8.0:2.0:0.05 v/v/v) and detection was carried out on 269 nm. The calibration curve was plotted over the concentration range of 200 ng to 600 ng. The average recoveries were 90.12% and 79.64% by LLE and SPE, respectively. The proposed method was validated as per US-FDA guidance.

ACKNOWLEDGMENTS

We acknowledge Ajanta Pharma Ltd. (Paithan, India) and Emcure Pharma Ltd. (Pune, India) for providing gift samples of Olmesartan Medoxomil and Zidovudine, respectively. We would like to thank Arpan Blood Bank, (Nashik, India) for providing human plasma for the research work. Authors are thankful to Prof. V. M. Aurangabadkar, Principal, M. G. V.'s Pharmacy College, Nashik for providing the necessary facilities for the research work.

Notes

a S.D. = Standard deviation.

b R.S.D. = Relative standard deviation.

c n = Number of determination.

a S.D. = Standard deviation.

b R.S.D. = Relative standard deviation.

c n = Number of determination.

c n = Number of determination.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.